CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nasal DexamethasoneWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1547 Laboratory tests Wiki 1.00
drug1366 IV Dexamethasone Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.08
D007239 Infection NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Randomized Clinical Trial of Nasal Dexamethasone as an Adjuvant in Patients With COVID-19

This Clinical Trial evaluates nasal administration of Dexamethasone as an adjuvant treatment strategy for non-critically ill hospitalized participants with SARS CoV-2 infection.

NCT04513184 Covid19 Drug: IV Dexamethasone Drug: Nasal Dexamethasone

Primary Outcomes

Description: Evaluation of the clinical status of patients after randomization, defined as a two point improvement in the WHO 7-point Ordinal Scale

Measure: Time of clinical improvement

Time: 10 days after randomization

Secondary Outcomes

Description: All-cause mortality rates at 28 days after randomization

Measure: Time-to-death from all causes

Time: 28 days after randomization

Description: Ventilator-free days, defined as alive and not requiring mechanical ventilation, at 10 days after randomization.

Measure: Time free from mechanical ventilation

Time: 10 days after randomization

Description: Virological measurements, including proportions with detection of viral RNA over time and measurements of viral RNA titer area under the curve (AUC).

Measure: Viral load

Time: 10 days after randomization

Description: Length of hospital stay in days

Measure: Length of hospital stay

Time: 10 days after randomization

No related HPO nodes (Using clinical trials)